Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | DDX3X | O00571 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20552643 | 0.86 | ABCG2 (0.47) | ALDH1A1LMNASMN1; SMN2MAPTTP53 | |
| SCHEMBL25781534 | 0.85 | ABCG2 (0.39) | HPGDKMT2ATSHRALDH1A1MEN1 | |
| SCHEMBL20552771 | 0.84 | MAPT (0.51) | HPGDKMT2ATSHRALDH1A1MEN1 | |
| SCHEMBL21764731 | 0.83 | SMN1; SMN2 (0.42) | HPGDKMT2ATSHRALDH1A1MEN1 | |
| SCHEMBL21749262 | 0.81 | ATM (0.43) | KMT2ATSHRMEN1HSD17B10LMNA | |
| SCHEMBL20551735 | 0.81 | TP53 (0.49) | HPGDKMT2ATSHRALDH1A1MEN1 | |
| SCHEMBL20552699 | 0.81 | MAPT (0.42) | HPGDKMT2ATSHRALDH1A1MEN1 | |
| SCHEMBL20552508 | 0.81 | SMN1; SMN2 (0.55) | HPGDKMT2ATSHRALDH1A1MEN1 | |
| SCHEMBL20552347 | 0.80 | ABCG2 (0.46) | ALDH1A1LMNASMN1; SMN2MAPTTP53 | |
| SCHEMBL20552353 | 0.79 | KMT2A (0.49) | KMT2ATSHRALDH1A1MEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | HPGD 1998/4885KMT2A 1804/4885TSHR 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.